[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Jameel A, Jamil SN: Safety of cytotoxic chemotherapy during pregnancy. J Pak Med Assoc; 2007 Sep;57(9):449-52
MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of cytotoxic chemotherapy during pregnancy.
  • OBJECTIVE: To To present an experience and results of treatment of pregnant cancer patients with cytotoxic chemotherapy from second trimester of pregnancy.
  • METHODS: Eighteen consecutive pregnant patients treated at Khyber Teaching Hospital, Peshawar between December 2000 and August 2006 for different types of malignancies are reported.
  • Six patients (33%) had breast cancer, four (22%) had chronic myeloid leukaemia, two (11%) had Hodgkin's disease, two (11%) had acute myeloid leukaemia and one each had recurrent ovarian carcinoma (5.7%), soft-tissue sarcoma (5.7%), acute lymphoblastic leukaemia (5.7%) and non-Hodgkin's lymphoma (5.7%).
  • RESULTS: Two patients were lost to follow-up after one course of chemotherapy while two patients chose to have therapeutic abortion.
  • Out of the remaining 14 patients, one patient had spontaneous abortion while one patient had an intra-uterine death of foetus during chemotherapy.
  • Six out of 140 breast cancer patients (4.3%) during the study period had concomitant pregnancy.
  • Four patients with breast cancer had modified radical mastectomy with axillary dissection during pregnancy (median gestational age 22 weeks) and no operative or post-operative complications were noted.
  • Three out of four breast cancer patients (75%) had hormone receptor negative tumours.
  • CONCLUSION: Chemotherapy during the second and third trimester of pregnancy can be safe if proper obstetric and radiologic monitoring is performed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cytotoxins / adverse effects. Drug-Related Side Effects and Adverse Reactions. Pregnancy Complications. Pregnancy Outcome
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasms / drug therapy. Pregnancy. Pregnancy Trimester, Second. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072640.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytotoxins
  •  go-up   go-down


2. Choi CW, Sung HJ, Park KH, Yoon SY, Kim SJ, Oh SC, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS: Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol; 2003 Aug;73(4):263-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.
  • Febrile neutropenia (FN) is a frequent complication of cancer chemotherapy, which causes death in 4-21% of patients and worsens the quality of life of patients.
  • As a simple and accurate way of identifying patients who are at risk of FN, a lymphocyte count on post-chemotherapy day 5 was suggested.
  • From September 2001 to February 2002, patients who received cytotoxic chemotherapy at Guro Hospital, Korea University, were enrolled.
  • Blood sampling for a complete blood count was done on the starting day of chemotherapy and on day 3 and day 5 post-chemotherapy.
  • Underlying malignancies were non-Hodgkin's lymphoma (14 patients), stomach cancer (17), breast cancer (11), NSCLC (7), hepatobiliary cancer (10), sarcoma (3), colorectal cancer (3), and others (17).
  • The incidence of FN was 18% (15/82 patients), and ANC at the time of FN was 275 +/- 327/ micro l.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Fever. Lymphopenia. Neutropenia / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Incidence. Lymphocyte Count. Male. Middle Aged. Neoplasms / complications. Neoplasms / drug therapy. Predictive Value of Tests. Prospective Studies. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12879430.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP: Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol; 2010 Mar 1;28(7):1232-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy.
  • PURPOSE: Survivors of childhood Hodgkin's lymphoma (HL) are at risk for second malignant neoplasms (SMNs).
  • We report the first long-term outcomes of a cohort of pediatric survivors of HL treated with chemotherapy and low-dose radiation.
  • PATIENTS AND METHODS: Pediatric patients with HL (n = 112) treated at Stanford from 1970 to 1990 on two combined modality treatment protocols were identified.
  • Treatment included six cycles of chemotherapy with 15 to 25.5 Gy involved-field radiation with optional 10 Gy boosts to bulky sites.
  • RESULTS: One hundred ten children completed HL therapy; median follow-up was 20.6 years.
  • Eighteen patients developed one or more SMNs, including four leukemias, five thyroid carcinomas, six breast carcinomas, and four sarcomas.
  • Cumulative incidence of first SMN was 17% (95% CI, 10.5 to 26.7) at 20 years after HL diagnosis.
  • For those with second solid tumors, the mean (+/- SE) 5-year disease-free and overall survival were 76% +/- 12% and 85% +/- 10% with median follow-up 5 years from SMN diagnosis.
  • CONCLUSION: Despite treatment with low-dose radiation, children treated for HL remain at significant risk for SMN.
  • Sarcomas, breast and thyroid carcinomas occurred with similar frequency and latency as found in studies of children with HL who received high-dose radiation.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Breast Neoplasms / epidemiology. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Male. Sarcoma / epidemiology. Survivors. Thyroid Neoplasms / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094069
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4872329
  •  go-up   go-down


Advertisement
4. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY, European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res; 2009 Jul 1;69(13):5383-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphopenia is frequent in advanced cancers and predicts the toxicity of chemotherapy.
  • Its prognostic value for survival was analyzed in three databases of previously reported prospective multicenter studies: (a) FEC chemotherapy in metastatic breast carcinoma;.
  • (b) CYVADIC in advanced soft tissue sarcoma (European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group 62791); and (c) prospective, consecutive phase III studies of aggressive diffuse large-cell non-Hodgkin's lymphomas conducted at Centre Léon Bérard between 1987 and 1993.
  • The incidence of lymphopenia of <1,000/microL before treatment was constant among the series: 25%, 24%, and 27%, respectively.
  • Lymphopenia was significantly more frequent (P < 0.05) in metastatic breast cancer patients with performance status (PS) of >1, non-Hodgkin's lymphoma patients with international prognostic index (IPI) of > 0, and advanced soft tissue sarcoma and metastatic breast cancer patients with bone metastases.
  • Inunivariate analysis, lymphopenia of <1,000/microL significantly correlated to overall survival in patients with metastatic breast cancer (median, 10 versus 14 mo; P < 0.0001), advanced soft tissue sarcoma (median, 5 versus 10 months; P < 0.01), and non-Hodgkin lymphoma (median, 11 versus 94 months; P < 0.0001).
  • In multivariate analysis (Cox model), lymphopenia was an independent prognostic factor for overall survival in metastatic breast cancer [RR (relative risk), 1.8; 95% CI (confidence interval), 1.3-2.4] along with liver metastases and PS; in advanced soft tissue sarcoma (RR, 1.46; 95% CI, 1.0-2.1) along with liver metastases, lung metastases, and PS; and in non-Hodgkin's lymphoma (RR, 1.48; 95% CI, 1.03-2.1) along with IPI.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):181-6 [12610500.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2294-9 [12411295.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4235-8 [14615453.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):710-20 [15146561.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):341-53 [15172354.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2371-8 [15197198.001]
  • [Cites] Cancer. 1970 Jan;25(1):135-40 [5410303.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):126-30 [6850535.001]
  • [Cites] Cancer. 1984 May 1;53(9):1825-32 [6367947.001]
  • [Cites] Stat Med. 1985 Jan-Mar;4(1):39-46 [3857702.001]
  • [Cites] Stat Med. 1986 Jul-Aug;5(4):303-17 [3764222.001]
  • [Cites] Bull Cancer. 1990;77(9):941-7 [2224167.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Eur J Cancer. 1994;30A(3):321-4 [8204352.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):575-82 [7884418.001]
  • [Cites] Nat Med. 1996 Mar;2(3):317-22 [8612231.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):636-43 [8636781.001]
  • [Cites] Stat Med. 1995 Dec 15;14(23):2581-98 [8746890.001]
  • [Cites] Nat Med. 1996 Dec;2(12):1361-6 [8946836.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5499-505 [8968107.001]
  • [Cites] Blood. 1998 Jul 15;92(2):405-10 [9657738.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1263-73 [10389908.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Leuk Lymphoma. 1999 Aug;34(5-6):519-27 [10492075.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2675-80 [15503313.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Cytokine. 2006 Feb 7;33(3):145-9 [16524740.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2855-62 [16357322.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):1066-70 [16552441.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Mar;23(2):143-51 [16651243.001]
  • [Cites] J Immunother. 2006 May-Jun;29(3):313-9 [16699374.001]
  • [Cites] Semin Hematol. 2006 Oct;43(4):213-20 [17027655.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2698-705 [17063500.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3317-22 [1596890.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1732-40 [17389336.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1209-15 [17496307.001]
  • [Cites] Invest New Drugs. 2010 Feb;28(1):76-82 [19205623.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):168-72 [17060489.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2840-6 [10561360.001]
  • [Cites] Nature. 1999 Nov 18;402(6759):255-62 [10580495.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):947s-957s [11300496.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):816-22 [11556830.001]
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):46-53 [11905837.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 12):1-3 [12170444.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2553-62 [12171883.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):719-27 [12473512.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):64-9 [12504660.001]
  • [Cites] Am J Hematol. 2003 Aug;73(4):263-6 [12879430.001]
  • (PMID = 19549917.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA011488-38; United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 5U10 CA011488-38; United States / NCI NIH HHS / CA / U10 CA011488-38
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS115478; NLM/ PMC2775079
  •  go-up   go-down


5. Sharpe M, Easthope SE, Keating GM, Lamb HM: Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs; 2002;62(14):2089-126
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.
  • Polyethylene glycol (PEG)-liposomal doxorubicin is a formulation of the anthracycline doxorubicin in which the drug is encapsulated in PEG-coated liposomes.
  • This alters the pharmacokinetic properties of doxorubicin, prolonging circulation time and enhancing localisation to tumours.
  • In a large randomised trial, intravenous PEG-liposomal doxorubicin was at least as effective as topotecan in patients with ovarian cancer refractory or sensitive to first-line platinum-based chemotherapy.
  • Overall response rates of patients with ovarian cancer refractory to platinum- and paclitaxel-based chemotherapy who received the drug ranged from 18.3 to 27.6% in noncomparative clinical trials.
  • PEG-liposomal doxorubicin also has antitumour activity in patients with metastatic breast cancer pretreated with other chemotherapeutic agents.
  • Overall response rates were similar in patients with pretreated metastatic breast cancer who had received PEG-liposomal doxorubicin or two comparator salvage chemotherapy regimens (vinorelbine or mitomycin C plus vinblastine) in an interim analysis of a large randomised study.
  • In patients with advanced AIDS-related Kaposi's sarcoma, PEG-liposomal doxorubicin monotherapy produced overall response rates ranging from 46 to 77% in randomised trials.
  • The drug was significantly more effective than bleomycin plus vincristine alone or in combination with standard doxorubicin, as measured by tumour response.
  • As a replacement for standard doxorubicin in commonly used combination therapies, PEG-liposomal doxorubicin has shown activity in multiple myeloma and aggressive non-Hodgkin's lymphoma in small, preliminary trials.
  • CONCLUSIONS: Monotherapy with PEG-liposomal doxorubicin is effective as a second-line chemotherapy in patients with platinum-refractory ovarian cancer and in patients with metastatic breast cancer.
  • However, as with all chemotherapeutic agents, the benefits of treatment need to be weighed against the agent's tolerability profile.
  • Strong comparative data have helped to establish PEG-liposomal doxorubicin as the first-line treatment option in patients with advanced Kaposi's sarcoma.
  • Anticancer activity has also been observed in studies conducted in small numbers of patients with multiple myeloma or non-Hodgkin's lymphoma receiving PEG-liposomal doxorubicin instead of standard doxorubicin in combination regimens, although further data are needed to confirm the clinical relevance of these findings.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Doxorubicin / administration & dosage. Hematologic Neoplasms / drug therapy. Polyethylene Glycols / administration & dosage. Sarcoma, Kaposi / drug therapy


6. Vernaeve V, Bodri D, Colodrón M, Vidal R, Durbán M, Coll O: Endometrial receptivity after oocyte donation in recipients with a history of chemotherapy and/or radiotherapy. Hum Reprod; 2007 Nov;22(11):2863-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial receptivity after oocyte donation in recipients with a history of chemotherapy and/or radiotherapy.
  • INTRODUCTION: Information is scarce regarding the outcome of oocyte donation (OD) in patients with a history of cancer treatment.
  • METHODS: Between January 2000 and November 2005, 33 patients with a history of chemotherapy and/or radiotherapy had an OD cycle.
  • Matching was performed to the chronologically closest patient without a history of cancer therapy by number of days of hormonal stimulation before embryo replacement, number of replaced embryos, day of embryo transfer and origin of sperm.
  • RESULTS: The primary diseases of the patients were Hodgkin's lymphoma (n = 12), non-Hodgkin's lymphoma (n = 3), leukaemia (n = 7), ovarian cancer (n = 6), Ewing's sarcoma (n = 2), breast cancer (n = 1), sympathoblastoma (n = 1) and histiocytosis X (n = 1).
  • Twenty-three patients had undergone chemotherapy and radiotherapy, nine patients chemotherapy only and one radiotherapy only.
  • CONCLUSIONS: The results suggest that patients with a history of cancer treatment have a pregnancy rate after OD similar to that in the general population of oocyte recipients.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Embryo Implantation. Endometrium / drug effects. Endometrium / radiation effects. Neoplasms / drug therapy. Neoplasms / radiotherapy. Oocyte Donation / methods. Radiotherapy. Sperm Injections, Intracytoplasmic / methods
  • [MeSH-minor] Adult. Female. Fertilization in Vitro / methods. Humans. Pregnancy. Pregnancy Outcome. Pregnancy Rate. Reproductive Medicine / methods. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855411.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Ridderheim M, Bjurberg M, Gustavsson A: Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer; 2003 Jun;11(6):371-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients.
  • GOALS: The aim of this study was to examine the efficacy and safety of a new digitized, controlled, scalp-cooling system to prevent chemotherapy-induced alopecia.
  • METHOD: Seventy-four female cancer patients who received 13 varying chemotherapy regimens were included in a nonrandomized pilot study.
  • In this study, 60 patients were treated for ovarian cancer with either taxane or epirubicin combination chemotherapy.
  • Eight patients with Hodgkin's lymphoma, three with breast cancer, two with endometrial cancer, and one with sarcoma were also included.
  • CONCLUSIONS: The digitized, controlled, scalp-cooling system represents an effective and safe device that should be clinically evaluated in a randomized trial and in studies using other chemotherapy regimens to determine optimal temperatures and durations of cooling for maximal efficacy.
  • [MeSH-major] Alopecia / chemically induced. Alopecia / prevention & control. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hypothermia, Induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Automation. Female. Humans. Middle Aged. Neoplasms / drug therapy. Scalp

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rep. 1987 Oct;71(10):913-4 [3477318.001]
  • [Cites] Eur J Cancer. 1994;30A(10):1448-53 [7833100.001]
  • [Cites] Prof Nurse. 1996 May;11(8):507-9 [8718338.001]
  • [Cites] Eur J Gynaecol Oncol. 1986;7(1):15-7 [3699056.001]
  • [Cites] Support Care Cancer. 1997 Mar;5(2):136-8 [9069614.001]
  • [Cites] Cancer Nurs. 1988 Jun;11(3):170-3 [3401852.001]
  • [Cites] Neth J Med. 1990 Dec;37(5-6):231-5 [2074916.001]
  • [Cites] Acta Radiol Oncol. 1985 Mar-Apr;24(2):113-6 [2988271.001]
  • [Cites] Postgrad Med J. 1988 Nov;64(757):907 [3255944.001]
  • [Cites] Scand J Clin Lab Invest. 1985 Oct;45(6):505-8 [4070952.001]
  • [Cites] Am J Clin Oncol. 1986 Oct;9(5):454-7 [3776909.001]
  • [Cites] Recent Results Cancer Res. 1988;108:117-26 [3051202.001]
  • [Cites] Semin Oncol. 1998 Oct;25(5):562-70 [9783595.001]
  • [Cites] Cancer Treat Rep. 1985 Apr;69(4):373-5 [3995509.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):297-300 [9135504.001]
  • [Cites] Cancer Treat Rep. 1981 May-Jun;65(5-6):507-8 [7237471.001]
  • [Cites] Nurs Times. 1987 Aug 12-18;83(32):36-7 [3650881.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):766-71 [10762750.001]
  • [Cites] Br Med J (Clin Res Ed). 1982 Jun 5;284(6330):1674 [6805650.001]
  • [Cites] Cancer Nurs. 1994 Aug;17(4):334-41 [7525048.001]
  • (PMID = 12768403.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. D'Costa GF, Hastak MS, Patil YV: Granulocytic sarcoma of breast: an aleukemic presentation. Indian J Med Sci; 2007 Mar;61(3):152-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of breast: an aleukemic presentation.
  • Granulocytic sarcoma is a rare extramedullary tumor composed of immature myeloid cells.
  • The breast is an uncommon site of presentation and requires a high index of suspicion for diagnosis.
  • We report such a case in a 45-year-old female, who presented with nontender left breast lump of 6 months' duration.
  • A peripheral smear and bone marrow examination at that time was normal.
  • An H and E diagnosis of lobular carcinoma vs. non-Hodgkin's lymphoma was entertained.
  • Immunostains, however, revealed myeloperoxidase, naphthol AS-D chloroacetate esterase and CD43 positivity, indicating a diagnosis of granulocytic sarcoma.
  • It appears that early initiation of systemic AML-type chemotherapy is beneficial and may delay or avert the development of AML in bone marrow and blood.
  • [MeSH-major] Breast Neoplasms / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / diagnosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337816.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / Naphthols; 35245-26-2 / naphthol AS-D chloroacetate; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


9. Fang Z, Matsumoto S, Ae K, Kawaguchi N, Yoshikawa H, Ueda T, Ishii T, Araki N, Kito M: Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan. J Orthop Sci; 2004;9(3):242-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan.
  • Radiation therapy (RT) is commonly used to treat malignant tumors, but it leads to side effects and complications.
  • This article focuses on the clinical manifestations, pathological characteristics, and therapeutic effects concerning postradiation soft tissue sarcomas (PRSTSs).
  • Their histological types were malignant fibrous histiocytoma (eight cases), extraskeletal osteosarcoma (four cases), fibrosarcoma (one case), and leiomyosarcoma (one case).
  • The primary diagnoses, RT history, latent period, and outcome of treatment were studied retrospectively.
  • The original tumors included uterine cancer (seven cases), breast cancer (four cases), synovial sarcoma (one case), squamous cell carcinoma (one case), and Hodgkin's disease (one case).
  • There were 13 women and 1 man, with ages ranging from 23 to 77 years (mean 58 years) at the time of the appearance of the PRSTS.
  • RT doses ranged from 48 to 91 Gy (mean 62 Gy).
  • Altogether, 4 of 13 patients (31%) had recurrence of the sarcoma after resection.
  • One of three who underwent RT and one of five who underwent chemotherapy (CT) responded.
  • Because adjuvant therapies including RT and CT had a poor effect on PRSTSs, the primary treatment of PRSTSs should be radical resection with a wide margin.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / radiotherapy. Female. Histiocytoma, Benign Fibrous / etiology. Histiocytoma, Benign Fibrous / surgery. Humans. Japan. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Uterine Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] The Japanese Orthopaedic Association
  • (PMID = 15168177.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


10. Quintas-Cardama A, Fraga M, Antunez J, Forteza J: Primary extramedullary myeloid tumor of the breast: a case report and review of the literature. Ann Hematol; 2003 Jul;82(7):431-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extramedullary myeloid tumor of the breast: a case report and review of the literature.
  • Breast is an uncommon location for PEMMT and only a few cases have been reported so far in the medical literature.
  • We reviewed all the reported cases of PEMMT of the breast in the English-language literature since 1965.
  • In addition, we present a new case of PEMMT of the breast who presented with a mass in her right breast mimicking a breast malignancy and was initially misdiagnosed as non-Hodgkin's lymphoma.
  • A careful histologic examination with immunohistochemical studies revealed the presence of PEMMT of the breast.
  • Treatment with systemic chemotherapy and local radiotherapy rendered a complete remission.
  • Seventeen cases of PEMMT of the breast were reported in the English literature from 1965 to 2003.
  • Most of the cases were misdiagnosed initially as lymphomas, breast carcinomas, or malignant melanomas.
  • PEMMT of the breast is a poorly recognized entity whose diagnosis frequently challenges both the pathologist and the oncologist.
  • Given the small number of patients reported no optimal treatment has been defined, but systemic chemotherapy similar to that given for acute myeloid leukemia with or without local radiotherapy may result in long remissions and avoid the progression to overt acute myeloid leukemia.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Neoplasm Invasiveness. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12768322.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


11. Łacko A, Włodarska I, Zymliński R, Mazur G, Wróbel T, Gisterek I: [Cardiac toxicity in cancer therapy]. Pol Merkur Lekarski; 2002 Jul;13(73):79-85
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac toxicity in cancer therapy].
  • The aim of this article is to review (based on the literature data) the mechanism of chemotherapy- and radiation-induced cardiac toxicity, diagnostic procedures and methods of reducing this toxicity.
  • Cardiac toxicity associated with chemotherapy and radiotherapy may be life threatening, can limit the dose and duration of the treatment and certainly adversely affect short-term and long-term quality of life.
  • The frequency of cardiomyopathy may be reduced by modifying the schedule of administration, patients selection considering risk factors, careful cardiac monitoring during chemotherapy, using less toxic doxorubicin analogues and liposomal formulation.
  • The use of pharmacological protection with dexrazoxane remains controversial.
  • Moreover, radiotherapy may have an additive affect to chemotherapy-induced toxicity.
  • However, with the use of modern treatment techniques radiation cardiomyopathy is uncommon.
  • A group of patients at risk of cardiac complication are patients with breast cancer, Hodgkin's and non-Hodgkin's lymphomas and soft tissue sarcomas.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Cardiomyopathy, Dilated / etiology. Neoplasms / drug therapy. Radiotherapy, Adjuvant / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Cardiovascular Agents / therapeutic use. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Hodgkin Disease / drug therapy. Humans. Lymphoma, Non-Hodgkin / drug therapy. Razoxane / therapeutic use. Risk Factors. Sarcoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12362515.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cardiovascular Agents; 5AR83PR647 / Razoxane
  • [Number-of-references] 39
  •  go-up   go-down


12. Ferrucci PF, Martinoni A, Cocorocchio E, Civelli M, Cinieri S, Cardinale D, Peccatori FA, Lamantia G, Agazzi A, Corsini C, Tealdo F, Fiorentini C, Cipolla CM, Martinelli G: Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Transplant; 2000 Jan;25(2):173-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy.
  • Peripheral blood progenitor cell reinfusion (PBPC) in patients undergoing high-dose chemotherapy (HDC) for poor prognosis malignancies, has been described as causing possible acute gastrointestinal (nausea, vomiting), allergic (oedema, bronchospasm, anaphyl- axis), renal (proteinuria, haematuria) and/or cardiovascular (hypotension, arrhythmia, conduction disturbances, transient ischaemic phenomena) toxicities.
  • To establish the clinical relevance of these observations and the possible relationship with different HDC regimens used, we performed a clinical and instrumental evaluation on 33 patients with advanced breast cancer, non-Hodgkin's lymphoma, Hodgkin's disease, relapsed ovarian cancer, Ewing's sarcoma, extragonadal germinal tumour and small cell lung cancer.
  • To evaluate cardiovascular function, we continuously monitored 12-lead ECGs, with arterial pressure (AP) measurements every 5 min from the beginning of the procedure to 15 min after the reinfusion ended.
  • We did not observe any significant differences between basal and subsequent steps in AP, heart rate, PQ and QTc time, P wave and QRS complex duration or P wave and QRS electrical axes.
  • No patient showed any ST-T tract pathological abnormality, but one patient developed a transient ectopic atrial rhythm, without any haemodynamic disfunction and with spontaneous reversion to sinus rhythm.
  • In one patient a tonic-clonic seizure occurred during a vomiting episode, but no patient developed allergic or renal toxicities.
  • We conclude that PBPC reinfusion, if managed according to the procedure we propose in patients without organic impairment, is a safe procedure not associated either with increased risk of acute arrhythmias or ischaemic or significant systemic acute toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Bone Marrow Transplant. 2002 Mar;29(6):544 [11960281.001]
  • (PMID = 10673676.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


13. Korman DB, Mikaélian SG, Boronovskaia LE, Maslova IA: [Results of a phase I-II clinical trial of Emoxyl, a novel antineoplastic anthracycline]. Vopr Onkol; 2004;50(2):202-7
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drug was given to 63 patients with different malignancies stages I-II.
  • Out of 55 cases evaluated for immediate effect, complete remission (breast cancer, small-cell cancer of the lung, Kaposi's sarcoma)--3; partial remission (breast cancer--2; non-Hodgkin's lymphoma--1)--3, and stabilization--26.
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Daunorubicin / analogs & derivatives. Daunorubicin / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Carcinoma, Small Cell / drug therapy. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Sarcoma, Kaposi / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15176224.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 84412-94-2 / Emoxyl; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


14. Gupta S, Kanodia AK: Biological response modifiers in cancer therapy. Natl Med J India; 2002 Jul-Aug;15(4):202-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological response modifiers in cancer therapy.
  • Monoclonal antibodies directed against tumour-specific agents have been approved for the treatment of breast cancer (trastuzumab), non-Hodgkin's lymphoma (rituximab) and for the diagnosis of certain cancers (oncoscint).
  • Interferons are indicated for the treatment of certain leukaemias and Kaposi's sarcoma to inhibit tumour proliferation and angiogenesis.
  • Haematopoletic growth factors are often combined with chemotherapy and radiotherapy to restore bone marrow function and treat complications such as infection and bleeding.
  • Various anticancer vaccines are being developed using tumour cells, carbohydrates, peptides and heat-shock proteins as antigens.
  • [MeSH-major] Immunologic Factors / therapeutic use. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12296474.001).
  • [ISSN] 0970-258X
  • [Journal-full-title] The National medical journal of India
  • [ISO-abbreviation] Natl Med J India
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Immunologic Factors
  • [Number-of-references] 80
  •  go-up   go-down


15. Latz D, Nassar N, Frank R: Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie; 2004 Dec;27(6):572-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trofosfamide in the palliative treatment of cancer: a review of the literature.
  • The main indications for application were in the palliative situation and as maintenance therapy.
  • Good results were reported from the treatment of non-Hodgkin's lymphomas and soft tissue sarcomas.
  • A lot of small studies and casuistic contributions are available giving treatment results of several solid carcinomas (malignant gliomas, ovarian, lung and prostate cancer, and others).
  • Due to its oral formulation and good tolerability trofosfamide is an attractive candidate for the palliative situation because treatment on an outpatient basis is possible.
  • Thus, evidence-based conclusions on the therapeutic value of the drug cannot be drawn.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Cyclophosphamide / analogs & derivatives. Cyclophosphamide / therapeutic use. Lymphoma / drug therapy. Palliative Care / methods. Sarcoma / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Neoplasms / drug therapy. Treatment Outcome


16. Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, Sartori S: Zoledronic acid treatment at home: safety data from an observational prospective trial. J Palliat Med; 2007 Apr;10(2):352-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid treatment at home: safety data from an observational prospective trial.
  • BACKGROUND: To prospectively assess feasibility, side effects, and safety of a home treatment with zoledronic acid in patients with bone metastases confined to home.
  • Primary end point of this observational trial was the safety assessment of the treatment at home; secondary end points were the clinical assessment of the time to treatment discontinuation and the definition of a pattern of patients who could benefit by a home treatment with intravenous bisphosphonates.
  • RESULTS: Nineteen patients had breast cancer; 7, multiple myeloma; 5, non-small-cell lung cancer; 4, renal cancer; 4, prostate cancer; 1, thyroid cancer; 1 non-Hodgkin's lymphoma; and 1 soft tissue sarcoma.
  • On the whole, 220 home treatments were administered in 3 years, with a median of 4 administrations per patient (range, 1-28).
  • Median time to treatment discontinuation was 130 days.
  • The treatment was interrupted for worsening of the performance status in 30 patients (71.4%), length of the treatment greater than 24 months in 2 patients (4.8%), hypocalcemia in 1 patient (2.4%), renal failure in 1 patient (2.4%).
  • No difference in median time to treatment discontinuation was observed among patients with breast cancer, multiple myeloma, or other tumors in univariate analysis.
  • Multivariate analysis showed no prognostic significance for kind of tumor, age at the time of entering the trial, gender, and number of extraosseous sites of disease.
  • No acute major side effects were observed during the treatment, and the treatment had to be interrupted for side effects in 2 patients (4.8%).
  • One patient had jaw osteonecrosis some months after the treatment was stopped.
  • CONCLUSIONS: The home treatment with zoledronic acid seems safe.
  • The appropriate use of biphosphonates in such a new setting needs a criterion to identify the subset of patients with bone metastases confined to home who can really benefit by this treatment.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / pathology. Diphosphonates / therapeutic use. Home Care Services. Imidazoles / therapeutic use. Multiple Myeloma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Creatinine / blood. Drug-Related Side Effects and Adverse Reactions. Feasibility Studies. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Observation. Prospective Studies. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Home Care Services.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472506.001).
  • [ISSN] 1096-6218
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; AYI8EX34EU / Creatinine
  •  go-up   go-down


17. Eilender D, LoRusso P, Thomas L, McCormick C, Rodgers AH, Hooper CL, Tornyos K, Krementz ET, Parker S, Morgan LR: 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers. Cancer Chemother Pharmacol; 2006 Jun;57(6):719-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers.
  • PURPOSE: This study is to document the activity and acceptability for a new topical agent, A-007, in the treatment of cutaneous metastases from cancer.
  • PATIENTS AND METHODS: This is a multicenter study involving 27 patients with inoperable skin lesions from histologically confirmed cancers of the breast and oral cavity, non-Hodgkin's lymphoma, Kaposi's sarcoma, and angiosarcoma that had failed radiotherapy or systemic treatment.
  • For patients with breast cancer, hormonal status did not have an impact on response.
  • All irritated areas cleared while continuing treatment, and the tumor lesions in the areas of itching also improved.
  • CONCLUSION: A-007, as a 0.25% gel, is confirmed as an effective palliative treatment option for cutaneous metastases from cancers.
  • Skin reactions were minimal, tolerated, and no cessation of treatment was required.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydrazones / therapeutic use. Phenols / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184382.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 49310; United States / NCI NIH HHS / CA / CA 89772
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone; 0 / Antineoplastic Agents; 0 / Hydrazones; 0 / Phenols
  •  go-up   go-down


18. Gorbunova VA, Orel NF, Semina OV, Egorov GN, Borodkina AG, Manziuk LV: [Aranoza -- a new Russian antineoplastic drug]. Vopr Onkol; 2001;47(6):672-5
Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aranoza -- a new Russian antineoplastic drug].
  • The drug proved effective in the treatment of uterine sarcoma, cancer of the head and neck, breast, Hodgkin's disease and lymphosarcoma during stage II of clinical studies.
  • Complete regression was reported in the treatment of melanoma (ca. 12%).
  • Clinical trials of aranoza used in combined modalities of therapy in various sites continue.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glycosides / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Methylnitrosourea / therapeutic use
  • [MeSH-minor] Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Drug Therapy, Combination. Humans. Infusions, Intra-Arterial. Multicenter Studies as Topic. Randomized Controlled Trials as Topic. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11826486.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glycosides; 0 / Interferon-alpha; 0 / aranoza; 684-93-5 / Methylnitrosourea
  •  go-up   go-down






Advertisement